Retatrutide – complimentary MARA Rating report: pricing & reimbursement risk assessment for obesity and metabolic disorders.
This complimentary MARA Rating® report assesses Retatrutide for obesity with or without metabolic disorders. The therapy achieved a MARA Score of 2.4 out of 4, corresponding to a Marginal (B++) rating. By comparison, the 5-year therapeutic area average is 2.8 and the industry-wide average is 3.0, indicating that Retatrutide’s rating falls below both benchmarks.
Clinical Effectiveness: A+ (Very Strong)
In a Phase 2 randomized controlled trial, Retatrutide demonstrated significant short-term weight loss compared to placebo. Mean body weight reduction ranged from -7.2% to -17.5% across dosing groups, versus -1.6% for placebo.
While the trial results are compelling, the absence of Phase 3 data leaves long-term efficacy uncertain.
Comparator Selection: A+ (Very Strong)
The Phase 2 study appropriately used placebo plus lifestyle intervention, aligning with standard care for obesity. Future trials are set to include active comparators such as tirzepatide, which will enhance the relevance of findings to clinical practice.
Care-Pathway Integration: A+ (Very Strong)
Retatrutide can be incorporated into current obesity treatment protocols without requiring new diagnostic tools or major structural changes. Its alignment with established clinical guidelines supports smooth integration into real-world practice.
About MARA Rating®
The MARA Rating synthesizes ten dimensions of market access risk – clinical efficacy, health-economic value, safety profile, comparator robustness, budget impact, and more – each scored on a seven-level scale (A++ to C).
We apply evidence-based weightings to generate a single risk score. A high MARA Score (A to A++) signals strong access prospects; a low score (B++ to C) denotes elevated pricing and reimbursement hurdles.
Unlock Premium Insights
Explore seven additional domains – Quality of Life (HRQoL), Cost-Effectiveness, Safety, Patient Population, Resource Use & Cost Implications, Evidence Quality, and Uncertainty – available exclusively in Premium Insights at mararating.com.
Full Premium Report available upon request: Visit mararating.com or email sales@mararating.com to learn more and unlock your access.
Access this report and hundreds of others: https://mararating.com/mara-ratings-list
Disclaimer: The MARA Rating® is an independent opinion of a drug’s market-access risk profile and is provided for informational purposes only – not as investment, medical, legal or any other type of advice. See our full disclaimer at mararating.com.